另外網站flotrac 適應症相關資訊 - 哇哇3C日誌也說明:flotrac 適應症,flotrac適應症:: 合法醫療器材資訊網,症照護、心血管疾病、加護病房、腦中風、長期照護、尿失禁等...師評估符合「經皮內視鏡胃造口」適應症的.
長庚大學 臨床醫學研究所 鄭美玲、余黃平所指導 蔡欣怡的 從臨床血液動力學到基礎代謝體學探討肝臟器官移植 (2018),提出FloTrac ppt關鍵因素是什麼,來自於肝臟移植、生物標記、血液動力學、代謝體學。
而第二篇論文國立臺灣師範大學 生命科學系 鄭劍廷所指導 吳峻宇的 手術條件下的靜脈輸液治療: 從基礎醫學研究到臨床醫學應用 (2016),提出因為有 腹部臟器微循環、膠體溶液、高張溶液、氧化壓力、肝硬化、動態輸液反應性指標、腦部手術的重點而找出了 FloTrac ppt的解答。
最後網站Stroke volume variation (SVV) and pulse pressure variation ...則補充:During inspiration (with positive pressure ventilation), the increase in intrathoracic pressure compresses the venae cavae. This subsequently reduces preload, ...
從臨床血液動力學到基礎代謝體學探討肝臟器官移植
為了解決FloTrac ppt 的問題,作者蔡欣怡 這樣論述:
指導教授推薦書……………………………………………………口試委員審定書……………………………………………………誌謝………………………………………………………………… iii中文摘要……………………………………………………………. vABSTRACT………………………………………………………… viiABBREVIATION………………………………………………….. ixChapter 1 Introduction on Liver Transplantation......................... 11.1 Types of Liver Tra
nsplantation……………………………... 21.1.1 De Novo Malignancies after Liver Transplantation from Taiwan’s Database……………………………. 41.1.2 Cardiovascular Disease Risks after Liver Transplantation from Taiwan’s Database……………. 71.2 Selection Criteria on Recipient……………………………... 101.3 Selectio
n Criteria on Living Donor………………………… 121.4 Intraoperative Monitoring and Management……………….. 141.4.1 Arterial Waveform Monitoring –FloTrac…………… 161.4.2 Electrical Velocimetry Monitoring System - Aesculon™………………………………………….. 181.5 Primary Graft Dysfunction…………………………………. 24Cha
pter 2 Introduction to Instrumentation in Metabolomic Analysis…………………………………………………………….. 272.1 Metabolomics……………………………………………….. 272.2 Nuclear Magnetic Resonance Spectroscopy……………………………………………………. 292.3 Mass Spectrometry…………………………………………. 312.4 Data Analysis……………………………………………….. 34Chapter
3 A Lipidomic Study of Early Allograft Dysfunction In Living Donor Liver Transplantation……………………………... 383.1 Methods and Materials……………………………………… 403.1.1 Patient Selection……………………………………… 403.1.2 Blood Samples……………………………………….. 413.1.3 NMR analysis of the plasma…………………………. 413.1.4 Liqui
d Chromatography coupled with Mass Spectrometry based Lipidomic…………………………….. 433.1.5 Ultra-performance liquid chromatography (UPLC)-based amino acid measurement…………………... 453.1.6 Statistical analysis……………………………………. 463.2 Results………………………………………………………. 473.2.1 Demographics and Clinical Dat
a…………………….. 473.2.2 Change in circulatory amino acid profiles in recipients with EAD……………………………………….. 483.2.3 Changes in NMR plasma profiles in recipients with EAD………………………………………………………… 483.2.4 Changes in circulatory lipid profiles in recipients with EAD………………………………………………………… 493.2.5 Dis
criminative ability of potential biomarkers for EAD and in-hospital mortality…………………………… 493.2.6 External validation of lipidomic profiling as prediction of EAD, long hospital stay and in-hospital mortality……………………………………………………. 503.3 Discussion……….………………………………………….. 513.3.1 Amino Acid………………
………………………...… 513.3.2 Lipids…………………………………………………. 523.3.3 Bilirubin……………………………………………… 55Chapter 4 Conclusion........................................................................ 56Chapter 5 Future Perspectives…………………………………... 59Chapter 6 Figures…………………………………………………. 60Figure 1. Flowchar
t of organ transplant recipients during 1996-201.. 60Figure 2. Flowchart of organ transplant patients during 1996-2011... 61Figure 3. Cumulative probability of any kind of vascular diseasefrom years after organ transplant…………………………………….62Figure 4. Cumulative probability of cardiovascular disease fro
myears after organ transplant…………………………………………..63Figure 5 Cumulative probability of cerebrovascular disease fromyears after organ transplant…………………………………………..64Figure 6. Cumulative probability of peripheral vascular disease fromyears after organ transplant…………………………………………..65Figure 7. Cumulative pro
bability of deep vein thrombosis fromyears after organ transplant………………………………………….66Figure 8. Modified formula of cardiac output analyses for theFloTrac algorithm…………………………………………………… 67Figure 9. Bland-Altman plot for COEv and COPAC………………… 68Figure 10. Four-quadrant plot for comparing changes in COEv
andCOPAC……………………………………………………………….69Figure 11. Schematic of the electrospray ionization process………... 70Figure 12. Flow diagram of the patient selection, allocation andanalysis……………………………………………………………… 71Figure 13. 1H NMR plasma profile model………………………….. 72Figure 14. 1H NMR plasma profile model………………
………….. 73Figure 15. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients inOPLS-DA plot……………………………………………………… 74Figure 16. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients in 75S-plot……………………………………
……………………………Figure 17. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients by classpermutation analysis………………………………………………… 76Figure 18. Prediction of early allograft dysfunction in study cohort... 77Figure 19. Prediction of long hospital stay in stud
y cohort…………. 78Figure 20. Prediction of all-cause in-hospital mortality in studycohort…………………………………………………………….......79Figure 21. Prediction of early allograft dysfunction in validationcohort………………………………………………………………...80Figure 22. Prediction of long hospital stay in validation cohort…….. 81Figure 23
. Prediction of all-cause in-hospital mortality in validationcohort ………………………………………………………………..82Figure 24. Schematic illustration of metabolic disturbancesassociated with poor outcomes of liver transplants………………… 83Chapter 7 Tables………………………..………………………….. 84Table 1. Risk of malignancies in liver tran
plant recipients………….. 84Table 2. Risk of vascular disease in liver transplant recipients……... 86Table 3. Summary of clinical data for living donor livertransplantation recipients……………………………………………. 87Table 4. Biochemical data for the patients before and after livertransplantation……………………………………………………
….88Table 5. Concentrations of amino acids at T6 in study group………. 90Table 6. A List of metabolites that discriminated the EAD from thenon-EAD groups …………………………………………………….91Table 7. Receiver operating characteristic (ROC) curve analysis forindividual metabolites in study and validation group……………….
93Table 8. Demographic details from the validation population……… 94Table 9. Biochemical details from the validation study population… 95Chapter 8 References…….………………………………………... 96Appendix……………………………………………………………. 112List of FiguresFigure 1. Flowchart of organ transplant recipients during 1996-201..
60Figure 2. Flowchart of organ transplant patients during 1996-2011... 61Figure 3. Cumulative probability of any kind of vascular diseasefrom years after organ transplant…………………………………….62Figure 4. Cumulative probability of cardiovascular disease fromyears after organ transplant…………………………………………..63Fi
gure 5 Cumulative probability of cerebrovascular disease fromyears after organ transplant…………………………………………..64Figure 6. Cumulative probability of peripheral vascular disease fromyears after organ transplant…………………………………………..65Figure 7. Cumulative probability of deep vein thrombosis fromyears after or
gan transplant………………………………………….66Figure 8. Modified formula of cardiac output analyses for theFloTrac algorithm…………………………………………………… 67Figure 9. Bland-Altman plot for COEv and COPAC………………… 68Figure 10. Four-quadrant plot for comparing changes in COEv andCOPAC……………………………………………………………….69Figure 11. Sche
matic of the electrospray ionization process………... 70Figure 12. Flow diagram of the patient selection, allocation andanalysis……………………………………………………………… 71Figure 13. 1H NMR plasma profile model………………………….. 72Figure 14. 1H NMR plasma profile model………………………….. 73Figure 15. Plasma samples analyzed by LC-M
S in electrospraypositive ion mode, comparing EAD and nonEAD recipients inOPLS-DA plot……………………………………………………… 74Figure 16. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients inS-plot………………………………………………………………… 75Figure 17. Plasma samples analyzed by LC
-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients by classpermutation analysis………………………………………………… 76Figure 18. Prediction of early allograft dysfunction in study cohort... 77Figure 19. Prediction of long hospital stay in study cohort…………. 78Figure 20. Prediction of all-cause
in-hospital mortality in studycohort…………………………………………………………….......79Figure 21. Prediction of early allograft dysfunction in validationcohort………………………………………………………………...80Figure 22. Prediction of long hospital stay in validation cohort…….. 81Figure 23. Prediction of all-cause in-hospital mortality in
validationcohort ………………………………………………………………..82Figure 24. Schematic illustration of metabolic disturbancesassociated with poor outcomes of liver transplants………………… 83List of TablesTable 1. Risk of malignancies in liver tranplant recipients………….. 84Table 2. Risk of vascular disease in liver transplant
recipients……... 86Table 3. Summary of clinical data for living donor livertransplantation recipients……………………………………………. 87Table 4. Biochemical data for the patients before and after livertransplantation……………………………………………………….88Table 5. Concentrations of amino acids at T6 in study group………. 90Table 6.
A List of metabolites that discriminated the EAD from thenon-EAD groups …………………………………………………….91Table 7. Receiver operating characteristic (ROC) curve analysis forindividual metabolites in study and validation group……………….93Table 8. Demographic details from the validation population……… 94Table 9. Bio
chemical details from the validation study population… 95
手術條件下的靜脈輸液治療: 從基礎醫學研究到臨床醫學應用
為了解決FloTrac ppt 的問題,作者吳峻宇 這樣論述:
靜脈輸液可視為一種藥物治療,為改善低血容狀態下身體循環的第一線治療方式,因此可算是所有外科病人最常接受到的治療項目。適當的靜脈輸液應包含三個層面:正確的輸液種類、正確的輸液時機以及正確的輸液總量,這三個層面只要有其中一項沒有達到,靜脈輸液便可能無法發揮療效,甚至導致傷害。靜脈輸液治療的目的,在於改善低血容狀態(例如:出血性休克)下的循環狀態。目前文獻已經證明,微循環(小於100微米小血管)的改善,比傳統大循環系統指標(如:平均動脈壓、心跳數),與預後有更高的關聯性。不同腹部臟器微循環,例如:肝、腎、腸組織,不但對低血容有不同的耐受度,也是病變發展成多器官衰竭的關鍵因子。治療低血溶狀態時,唯有
改善腹部臟器微循環才可真正預防不可逆的器官傷害。因此本論文的第一部分前半段,乃是利用雷射斑駁影像技術,發展出可即時同步觀察在出血性休克時,腹部臟器微循環變化的大鼠模型。我們發現雖然微循環血氧濃度在各腹部臟器中,有等量下降的狀態,但以腸黏膜微循環血流量對於出血性休克有最差的耐受性,相對之下,肝腎與周邊肌肉組織的微循環血流量則有較佳的耐受性。而本論文的第一部分後半段,則希望進一步探討臨床上常使用的靜脈液體製品包含晶體溶液(如:0.9%食鹽水)、膠體溶液(如:澱粉製品與明膠製品)以及高張溶液(如:3%食鹽水),在出血性休克狀態下,對腹部臟器微循環的療效差異。以不同種類靜脈輸液治療,不僅可能會造成不同
程度的循環改善,也可能伴隨不同程度的缺血再灌流症狀而造成不等量的氧化壓力。在腹部臟器中,以腎臟有最明顯的缺血再灌流效應。臨床上,以治療膠體溶液治療重症病人的低血溶狀態,被發現有較高機率在治療後發生急性腎損傷,這個現象可能與缺血再灌流與氧化壓力有關。因為氧化壓力產物有極短的半衰期,因此我們利用活體自由基偵測技術,精確定量大鼠在出血性休克下與靜脈輸液治療後,腎組織活體自由基產生的變化。我們發現,以靜脈輸液治療出血性休克,晶體溶液無法改善腸黏膜微循環血流量,只有膠體溶液與高張溶液可有效改善腸黏膜微循環血流量。但是膠體溶液,包含澱粉製品以及明膠製品,相較於晶體溶液與高張溶液,會產生極大量的腎臟自由基,
此現象極有可能與臨床文獻觀察到膠體溶液造成的急性腎損傷相關。總結本論文第一部分的前半與後半段,我們發現到腸黏膜微循環血流量對於出血性休克狀態下有最明顯的損傷,臨床的靜脈輸液治療僅有膠體溶液與高張溶液可以有效改善腸黏膜微循環血流量。但是使用膠體溶液治療時,有可能造成缺血性再灌流症狀而產生大量腎臟氧化壓力而導致急性腎損傷。臨床上,如何精確判斷適當的靜脈輸液量時機。目前臨床上最適合的輸液指標,當屬動態輸液反應性指標。這類指標可反映出在正壓呼吸下,心臟與肺部間相互影響下的變異率。體容越低的狀態下,心臟受到呼吸的吸氣期與吐氣期的擠壓影響變越大,反映在同一個呼吸週期下的脈搏壓、心輸出量的變異率變越大。因此
當動態輸液反應性指標反映出變異率高過閾值時,給予靜脈輸液便有極高機率可提升心輸出量(此現象稱之為「輸液反應性」),進而改善循環。但這類指標過去多半是在血管張力正常的病人中被應用,而臨床上有某一些特殊病理狀態會造成血管張力的異常,例如:肝硬化的患者,因為體內血管擴張物質無法被正常代謝,而有周邊血管阻力大幅下降的特徵。但是動態輸液反應性指標,卻從未在肝硬化病人身上證實有效。本論文的第二部分,探討我們在肝硬化病人,驗證目前臨床上最常見的三種動態輸液反應性指標,包括:脈搏壓變異率、心搏量變異率以及指端血容積變異率,是否在肝硬化病人也適用。結果我們發現,這三個指標在肝硬化病人身上,雖然較其他外科病人有較
為下降的準確度,仍保有臨床實用的偵測度,足以幫助臨床醫師,判斷肝硬化病人是否可藉由靜脈輸液而改善心輸出量與循環。本論文的第三部分,希望探討如何判斷正確的靜脈輸液總量,而此議題針對不同的手術器官,可能存在不同的標準。因為若器官沒有缺血風險存在,則即使在靜脈輸液可提升心輸出量而改善循環的時機下,過量的輸液仍可能導致組織水腫而造成傷害。以腦部手術而言,此類的臨床判斷充滿挑戰性。因為腦部組織佔總體心輸出量的比例極高,尤其在手術過程中可能有更高的血流量需求,但同時過多的輸液也可能因腦組織水腫而造成傷害。前述之動態輸液反應性指標,研究證實存在著一個「灰色地帶」,在此區間的下界限值與上界限值,分別代表了對輸
液反應性高特異度與高敏感度的狀態,亦即手術中輸液若以下界限值與上界限值為目標,分別代表著儘量輸液增加心輸出量與謹慎(限制性)輸液以避免過多體液的輸液策略。依此特性,我們在腦部切除手術患者,驗證究竟腦部手術的靜脈輸液量較適合在動態輸液反應性指標灰色地帶的上界或下界。研究結果發現,靜脈輸液控制在下界的患者,有較短的加護病房停留時間、較少的術後神經學症狀、較佳的出院日常生活功能性評分、較少的術中乳酸堆積,以及較少的術後血清神經專一性蛋白表現。證實接受腦部手術患者,術中輸液量應以儘量增加心輸出量為目標,才是較佳的輸液策略。靜脈輸液治療在手術狀態下的重要性,在現代醫學的進步下,不但沒有減少,反而更加重要
。總結本論文的發現,我們從基礎醫學的動物模型探討腹部臟器微循環在低血容下的病理變化,進一步證實高張溶液與膠體溶液對腸黏膜微循環的效果,並且發現膠體溶液對於腎臟缺血再灌流的現象可能與急性腎損傷相關。進一步到臨床應用上,證實動態輸液反應性指標此類參數,在肝硬化此類血管張力特殊變化的病人,仍然足夠精確幫助臨床醫師判斷靜脈輸液的時機點。最後,在腦部手術中,證實靜脈輸液量已儘量增加心輸出量的目標的策略,對於預後有較佳的效果。對於靜脈輸液治療中,「正確的輸液種類、正確的輸液時機以及正確的輸液總量」這三個層面,未來有更進一步機制的探討,將有機會更加增進手術患者的臨床照護。我們的研究從此觀點出發,未來,也將在
此層面做出更深入的探討。
想知道FloTrac ppt更多一定要看下面主題
FloTrac ppt的網路口碑排行榜
-
#1.免費蓮花圖
COM Lovepik提供海量的蓮花設計素材免費下載,下載更多有關蓮花的平面設計模板,背景圖片,創意插畫,免扣圖形矢量,高清攝影照片和PPT辦公模板素材,支持個人和商業 ... 於 jongbelegentheater.nl -
#2.Masimo LiDCO™ Hemodynamic Monitoring System
Uses already existing arterial line and blood pressure transducer to monitor hemodynamic parameters; PulseCO™ algorithm converts beat-to-beat blood pressure ... 於 www.masimo.com -
#3.flotrac 適應症相關資訊 - 哇哇3C日誌
flotrac 適應症,flotrac適應症:: 合法醫療器材資訊網,症照護、心血管疾病、加護病房、腦中風、長期照護、尿失禁等...師評估符合「經皮內視鏡胃造口」適應症的. 於 ez3c.tw -
#4.Stroke volume variation (SVV) and pulse pressure variation ...
During inspiration (with positive pressure ventilation), the increase in intrathoracic pressure compresses the venae cavae. This subsequently reduces preload, ... 於 www.deltexmedical.com -
#5.Goal-Directed Fluid Therapy Based on Stroke Volume ...
The FloTrac/Vigileo system provides automatic and continuous monitoring of the cardiac output, stroke volume, and stroke volume variation ... 於 www.karger.com -
#6.Methods for Assessing Fluid Responsiveness - YouTube
FloTrac sensor setup on EV1000 monitor. Edwards Lifesciences Clinical Education. Edwards Lifesciences Clinical Education. 於 www.youtube.com -
#7.Fluid Response Evaluation in Sepsis Hypotension and Shock
Fluid responsiveness prediction using Vigileo FloTrac measured cardiac output changes during passive leg raise test. J Intensive Care. 於 journal.chestnet.org -
#8.【flotrac ppt】資訊整理& flotrac相關消息| 綠色工廠 - Easylife
flotrac ppt,EV1000 簡易操作說明,FloTrac. (含A-Line). ProAQT. (不含A- ... FloTrac. 當心跳大於140下/分,無法測得心輸出量... FloTrac. 僅只有傳感器. 於 easylife.tw -
#9.47_Di Battista-Savelli.pdf - SIGG
FloTrac -Vigileo,. PRAM (autocalibrazione) ... With permission from Prof B Smith http://www.slideshare.net/uscompres/volume-responsiveness. 於 www.sigg.it -
#10.Certified Donation Partner Workshop - LifeSource
Arterial line and Flotrac can also provide helpful information in management of a potential lung donor. • ABG's. • Fluid status. 於 www.life-source.org -
#11.PiCCO • LITFL • CCC Equipment
PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique; PiCCO2 includes continuous ScvO2 ... 於 litfl.com -
#12.血液動力學監測之PiCCO 篇~~~讓你在加護病房深入了解它
是利用經肺溫度稀釋法(transpulmonary thermodilution)和脈搏曲線分析法(pulse contour analysis)。PiCCO測量需要放置中心靜脈導管及PiCCO動脈導管, ... 於 msicu1.pixnet.net -
#13.Cardiac output monitoring - si.mahidol
FloTrac ®/Vigileo®. Pulse contour and pulse pressure variation. +. -. NiCO®. Partial CO2rebreathing. +. -. Transesophageal echocardiography. 於 www.si.mahidol.ac.th -
#14.PiCCO plus
侵入性較小. - 只需要中央靜脈導管和PiCCO動脈導管. - 無需使用肺動脈順流導管. - 適用於小兒病患及體型瘦小病人. 於 www1.cgmh.org.tw -
#15.ADVANCED HEMODYNAMIC MONITORING IN CHILDREN
Manecke, G.R., Edwards FloTrac sensor and Vigileo monitor: easy, accurate, reliable cardiac output assessment using the arterial pulse wave. Expert.Rev.Med. 於 nvic-academy.nl -
#16.目标导向的血流动力学管理-PPT文档资料 - 百度文库
FloTrac + PreSep FloTrac / PreSep Swan-Ganz 低危病人 手术后病人 不以呼吸循环障碍为主要原因的入住ICU 病人监测内容: 一、前负荷参数:CVP HR 二、心肌收缩力 ... 於 wenku.baidu.com -
#17.VolumeView en críticos. Manejo de enfermería. ( por Alba ...
Flotrac : se trata de una línea arterial relativamente invasiva que se conecta al monitor EV1000. Este sistema es de uso más habitual en UCIs ... 於 elenfermerodelpendiente.com -
#18.From A-line to A-line CCO 中國醫藥 大學北港附設醫院 麻醉科
A-line CCO: FloTrac, MostCare, ProAQT, LiDCO rapid. 2.Esophageal Doppler monitor: CardioQ™. 3.Thoracic bioreactance technique, ⽣生物電抗: NICOM™, Aesculon™. 於 www.vghtc.gov.tw -
#19.FloTrac system | Edwards Lifesciences
FloTrac system—a minimally invasive solution (arterial line) that provides dynamic and flow-based hemodynamic parameters. 於 www.edwards.com -
#20.Perioperative fluid management in kidney transplantation
There are few devices using PCA technology: FloTrac/Vigileo/EV1000 system (Edwards Lifesciences, Irvine, CA, USA), LiDCOrapid (LiDCO, ... 於 ccforum.biomedcentral.com -
#21.Clinical evaluation of the FloTrac/Vigileo TM system and two ...
Assessment of cardiac output (CO) by the FloTrac/Vigileo™ system may offer a less invasive means of determining the CO than either the pulmonary artery catheter ... 於 www.bjanaesthesia.org -
#22.Changing Perceptions: Goal Directed Fluid Therapy
obtained from the FloTrac/ClearSight minimally invasive hemodynamic monitor ... educational session Power Point presentation will serve as a reference for ... 於 stormanesthesia.com -
#23.Cardiac output - Wikipedia
In cardiac physiology, cardiac output (CO), also known as heart output and often denoted by ... 2.2.2.2 Statistical analysis of arterial pressure – FloTrac/Vigileo ... 於 en.wikipedia.org -
#24.FloTrac ppt、proaqt操作、flotrac醫學在PTT/mobile01評價與討論
在FloTrac ppt這個討論中,有超過5篇Ptt貼文,作者jamesxxx1997也提到各位大大好,小弟是一名醫學大學的二年級學生以自己的學習狀況,會發現跟不上上課老師的教學速度 ... 於 hospital.reviewiki.com -
#25.Clinical Uses and Limitations of the FloTrac Monitoring System
Background: The Edwards Lifesciences FloTrac Monitoring System can be utilized in ... Appendix C. Power Point Presentation ... 於 repository.ahu.edu -
#26.Haemodynamic Monitoring in the Intensive Care Unit
Devices like the FloTracTM/EV1000TM system (Edwards Lifesciences, USA) allow pulse contour analysis of the arterial waveform acquired from ... 於 www.intechopen.com -
#27.【flotrac ppt】EdwardsFloTracSensor&Edwar... +1 | 健康跟著走
flotrac ppt :EdwardsFloTracSensor&Edwar... ... Edwards FloTrac Sensor & Edwards Vigileo MonitorThe Vigileo monitor by Edwards Lifesciences supports both the ... 於 tag.todohealth.com -
#28.Stroke Volume Variation “Can We Use Fluid to Improve ...
hemodynamics?” and, “Is it the appropriate intervention?” Stroke volume variation (SVV) as available on the FloTrac system may help answer these questions. 於 anesthesia.ucsf.edu -
#29.#flotrac - Twitter Search / Twitter
See Tweets about #flotrac on Twitter. ... FLOTRAC JR new trademark application by Edwards Lifesciences Corporation ... flotrac vigileo PowerPoint Slides ... 於 mobile.twitter.com -
#30.Hemodynamic Monitoring - Christiana Care Clinical Pathways
ClearSight and/or FloTrac monitoring can be used on any patient population; Care pathway patients, recurring ventral hernia patients will be monitored preop ... 於 pathways.christianacare.org -
#31.The Accuracy of the Vigileo/FloTrac System Has Been ...
View Large Image · Figure Viewer · Download Hi-res image · Download (PPT). 於 www.jcvaonline.com -
#32.fluid responsiveness - ICU One Pager
Some are uncalibrated (FloTrac), or calibrated (LiDCO [Li dilution], PiCCO [transpulmonary thermodilution using a temperature sensing arterial line]. 於 onepagericu.com -
#33.Flotrac - Slideshare
uses and limitation of flotrac - way to monitor cardiac output. 於 www.slideshare.net -
#34.Presentation Title - IN.gov
(FloTrac, LiddCo, PICCO). OR, ICU. Difficult. Fair. -. NICO. OR, ICU. Difficult. Fair. -. PAC. OR, ICU. Difficult. Good. $$. Bioreactance. OR, ICU. Good. 於 www.in.gov -
#35.01-Vigileo&FloTrac-工作原理及介绍.ppt - 皮匠网
经外周动脉连续心排量监测技术,爱德华上海医疗用品有限公司,SVV的定义,Stroke Volume Variation 每搏量变异度在机械通气情况下,由于呼吸机的作用引起 ... 於 m.3mbang.com -
#36.anaesthesia ppt - iMedScholar
set 1. Anesthesia Lecture Notes. Powerpoint links collected from the website of : Faculty of Medicine, Ain Shams University. Obstetric Anesthesia. 於 imedscholar.com -
#37.Síndrome de bajo gasto cardíaco en el posoperatorio de ...
Los sistemas FloTRac/Vigileo, ProAQT/PulsioFlex y LiDCOrapid son ejemplos de métodos mínimamente invasivos, que a través del análisis de la ... 於 www.scielo.edu.uy -
#38.Presentación de PowerPoint - medicina-intensiva.cl
Vigileo/Sistema Flotrac. •. Sistema de monitorización mínimamente invasiva. •. La presión de pulso es proporcional al VS e inversamente ... 於 www.medicina-intensiva.cl -
#39.Cardiac Output Measurement | Critical Care | AccessMedicine
pulse contour analysis requiring patient demographic and physical characteristics for arterial impedance estimation, that is, the FloTrac system (Edwards ... 於 accessmedicine.mhmedical.com -
#40.利用FloTrac 围手术期液体管理及监测PowerPoint Presentation
张钰整理编辑2013-10-18. 经外周动脉心输出量及血氧定量监测:. PreSEP 导管( 中心静脉). ScVO2. Vigileo 仪器. 心排量. FloTrac 传感器( 外周动脉). 床旁 ... 於 www.slideserve.com -
#41.FloTrac Sensor & Vigileo Monitor - ppt video online download
Disclaimer Despite an intense effort to find less invasive ways to measure cardiac output, there is NO data that conclusively proves that PA catheters harm ... 於 slideplayer.com -
#42.Arterial waveform analysis - SEMES
This device consists of a standard arterial catheter and a standard arterial line, which is connected to a disposable specific pressure transducer (“FloTrac”). 於 www.semes.org -
#43.Anesthetic management of a patient with heart failure and ...
... internal jugular vein and radial artery were cannulated, which were later connected to the EV1000 monitor through FloTrac transducer. 於 www.theiaforum.org -
#44.Systemic vascular resistance has an impact on the reliability of ...
Haemodynamic variables including CO measured by the Vigileo-FloTrac system (version 3.02) (APCO), CO measured by a pulmonary artery catheter (ICO), and SVR ... 於 www.bjanaesthesia.org.uk -
#45.Cardiac Output Monitoring by Pulse Contour Analysis ... - NCBI
由 J Grensemann 著作 · 2018 · 被引用 35 次 — The Vigileo™ monitor uses the proprietary FloTrac™ transducer that is attached to a standard radial or femoral arterial catheter. No external ... 於 www.ncbi.nlm.nih.gov -
#46.Anaesthesia for head and neck cancer surgery - BJA Education
Cardiac output monitoring based on pulse contour analysis such as LiDCO® or FloTrac® is preferred as nasal oesophageal Doppler probes are easily dislodged ... 於 www.bjaed.org -
#47.Stroke Volume Optimization Algorithm.pdf - FloTrac System...
FloTrac SystemStroke Volume Optimization% Change in Stroke Volume (∆SV) is a sensitive method forassessing preload responsiveness on all patients. 於 www.coursehero.com -
#48.智能化的血流动力学管理PPT讲座视频第一届粤港澳大湾区麻醉 ...
... 血流动力学深度监测技术,在国内率先应用FloTrac/Vigileo、PICCO、EV1000、LiDCO、阻抗技术等为代表的微创、无创血流动力学管理技术,从2009年开始,连续9年举办血 ... 於 www.wfns2019.org -
#49.FloTrac Guidelines Patient selection: Technical requirements
The Edwards Lifesciences FloTrac is a pulse-contour based hemodynamic monitoring system requiring only an arterial catheter for insertion. 於 www.aast.org -
#50.Preliminary experience with continuous right ventricular ...
... cardiac output was either measured using model-simulated cardiac output (FloTrac, Edwards LifeSciences Pty. ... PPT. PowerPoint slide. 於 journals.plos.org -
#51.Hemorrhagic Shock Definition - STRAC
FloTrac /Vigileo (Edwards). Near Infrared Spectroscopy (NIRS). Skeletal muscle StO2. Measures hemoglobin oxygen saturation in tissue; Tracks systemic O2 ... 於 www.strac.org -
#52.Improving postoperative outcomes in cardiac surgery | MDER
Efficacy of Intraoperative Hemodynamic Optimization Using FloTrac/EV1000 Platform for Early Goal-Directed Therapy to Improve Postoperative ... 於 www.dovepress.com -
#53.Anesthesia for Esophageal Surgery
Edwards FloTrac sensor and Vigileo monitor: easy, accurate, reliable cardiac output assessment using the arte- rial pulse wave. Expert Rev Med Devices. 於 www.mcgill.ca -
#54.Técnicas disponibles de monitorización hemodinámica ...
Sin embargo, el porcentaje de error del FloTrac/Vigileo® comparado con el CAP en pacientes obesos (IMC > 30kg/m2) fue ligeramente más alto que en pacientes con ... 於 www.medintensiva.org -
#55.vigileoflotrac工作原理及介绍ppt课件 - 豆丁网
第10页/共38页经外周动脉心输出量及血氧定量监测: Vigileo 仪器PreSEP 导管(中心静脉) ScvO ScvO 22 心排量心排量FloTrac 传感器(外周动脉) 第11页/共38页FloTrac ... 於 m.docin.com -
#56.Anaesthesia during oesophagectomy - Veelo
Usefulness of stroke volume index obtained with the FloTrac/ Vigileo system for the prediction of acute kidney injury after radical esophagectomy. 於 jtd.amegroups.com -
#57.Evaluation of a minimally invasive non–calibrated pulse ...
Evaluation of a minimally invasive non–calibrated pulse contour cardiac output monitor (FloTrac/Vigileo) in anaesthetized dogs. 於 www.vaajournal.org -
#58.加護病房內的血液動力學監測– Hemodynamic monitoring in ICU
☆ 後負荷指周邊血管阻力。 ☆ 而心搏輸出量(Stroke Volume) 會受到前負荷(容積多少) 與心臟收縮力的影響。 ☆ Chest 2006 ... 於 renaimed.net -
#59.外科加護病房- SICU: ICU演講
FloTrac System評估診斷系統 · 資訊 · ICU PAD 104.12.23在職教育.ppt, 資訊 · SICU Book · 腸阻塞.ppt · 轉診與病患安全. 搜尋課程: 您尚未登入(登入). 於 lms.tzuchi.com.tw -
#60.FloTrac Vigileo Training - PowerPoint PPT Presentation
PowerPoint PPT presentation. Number of Views:3537. Avg rating:3.0/5.0. Slides: 22. Provided by: benp3. Category: Tags: flotrac | calculation | training | ... 於 www.powershow.com -
#61.Actualización en Monitoreo Hemodinámico
Flotrac. Requiere introducir en la plataforma datos como. Sexo, Edad,. Estatura y Peso. Principio: VS es proporcional a la PP. Enf. Sylvia Vargas Molina. 於 www.euindisa.cl -
#62.(Microsoft PowerPoint - \270\255\250|\271\374.ppt)
CCO (FloTrac sensor, Edwards). Simplified Physiologic Protocol. Developed by W.T. McGee, MD, MHA, Tufts University Medical School ... 於 www.seccm.org.tw -
#63.Edwards Lifesciences - StudyLib
Related documents. FloTrac System - Edwards Lifesciences · Jonathan Edwards - Butler County Schools ... Edwards Syndrome- Trisomy 18.ppt - GeneticsProject. 於 studylib.net -
#64.HemoSphere Advanced Monitoring Platform - NET
FloTrac Sensor. Setup guide. HemoSphere advanced monitor screen features. To zero with the stopcock off to the patient and open to air:. 於 edwardsprod.blob.core.windows.net